10480 Wateridge Circle
98 articles with Inovio Pharmaceuticals
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that it has completed enrollment in the company's open-label, 24 patient, Phase 2 trial with its lead immunotherapy product VGX-3100 in patients with precancerous lesions of the anus, i.e. anal high-grade squamous intraepithelial lesions (anal HSIL, aka anal intraepithelial neoplasia)
Inovio Pharmaceuticals, Inc. reported financial results for the second quarter ended June 30, 2019.
Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea
Inovio Intends to Pursue Secondary Listing on Korea Exchange (KRX)
Following the release, the company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the second quarter 2019.
This latest publication underscores the potential for rapid deployment of Inovio's DNA vaccines.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
Inovio Pharmaceuticals, Inc. announced that it has sharpened its corporate strategy to focus on the commercial development of its late-stage HPV assets and reallocate capital to develop fast-to-market product candidates.
Geneos Therapeutics Announces First Patient Dosed with its DNA-based, Neoantigen-Targeting Personalized Vaccine Technology
This is the First-in-Human Implementation for Geneos Therapeutics' Exquisitely Personalized Immunotherapies for Cancer (GT-EPIC) Platform Clinical collaboration with Washington University
Inovio Completes Enrollment of VGX-3100 Phase 2 Trial for the Treatment of HPV-Related Vulvar Dysplasia (VIN)
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it has completed enrollment in its Phase 2 trial with VGX-3100 in patients with precancerous lesions of the vulva or vulvar intraepithelial neoplasia (VIN).
Inovio Completes Enrollment of VGX-3100 Phase 3 Trial (REVEAL 1) for the Treatment of HPV-Related Cervical Pre-cancer
If approved, VGX-3100 would be the first immunotherapy and non-surgical alternative for women with late-stage cervical dysplasia.
Inovio Receives $8.14 Million Award to Support Further Development of its Commercial Skin Delivery Device
In addition to the development of CELLECTRA 3PSP, the new award will fund the investigation of DNA vaccines developed by the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) using the new device.
Subjects dosed in First-in-Human study of INO-4500 funded by the Coalition for Epidemic Preparedness Innovations
QIAGEN and Inovio Collaborate to Develop Companion Diagnostic for Novel Immunotherapy Targeting Precancerous Cervical Lesions
Liquid biopsy-based Precision Medicine test to guide patient selection for Inovio’s VGX-3100
Inovio and Plumbline Life Sciences Establish Animal Health Collaboration to Develop A Novel Vaccine Against Deadly African Swine Fever Virus
Inovio Pharmaceuticals Inc. and Plumbline Life Sciences announced a collaboration to co-develop a novel animal health vaccine for African swine fever virus.
Inovio Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2019.
Inovio Receives European Medicines Agency Certification For Quality and Non-Clinical Data for Its Phase 3 Product, VGX-3100
The procedure of certification of quality and non-clinical data involves an assessment of the available data in view of future registration and the related European Scientific Data Requirements, not including any clinical data or benefit-risk assessment.
Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019.
Inovio Publishes Cancer Killing Data of Its Transformative DNA-encoded Bi-specific T Cell Engagers (dBiTEs™) in a Peer-reviewed Journal
Data demonstrates tumor-clearing ability of Inovio's dBiTE
The Vaccine Industry Excellence Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.
The milestone achievement for this multi-indication trial is the third MEDI0457-related Phase 2 milestone from AstraZeneca; two previous milestone payments resulted from initiating Phase 2 combination trials targeting head and neck and cervical cancers. Financial arrangements were not disclosed.